Patients suffering from chronic obstructive pulmonary disorder (COPD) now have a new option in terms of long-term symptom management. On July 23, the U.S. Food and Drug Administration (FDA) approved a new drug for COPD called Tudorza Pressair. Also known in the medical community as aclidinium bromide, it is made by Forest Pharmaceuticals in St. Louis, Missouri. This medication is designed to improve airflow to enhance your overall quality of life.
One of the main complications of COPD is bronchospasm, which causes constriction within the airways of the lungs. The goal of Tudorza Pressair is to relax airway muscles to reduce constriction. Patients who take this medication may be able to breathe easier because their airways will function better.
Continue Reading